These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 17307289

  • 1. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E.
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [Abstract] [Full Text] [Related]

  • 2. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A, Poewe W.
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [Abstract] [Full Text] [Related]

  • 3. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.
    N Engl J Med; 2007 Jan 04; 356(1):39-46. PubMed ID: 17202454
    [Abstract] [Full Text] [Related]

  • 4. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY, Chung EJ, Park SW, Lee WY.
    Mov Disord; 2006 Aug 04; 21(8):1261-4. PubMed ID: 16685692
    [Abstract] [Full Text] [Related]

  • 5. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB, Reimold SC, O'Suilleabhain PE.
    Arch Neurol; 2007 Mar 04; 64(3):377-80. PubMed ID: 17353380
    [Abstract] [Full Text] [Related]

  • 6. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E.
    N Engl J Med; 2007 Jan 04; 356(1):29-38. PubMed ID: 17202453
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G, Fuhrmann JT, Strasser RH.
    Mov Disord; 2007 Oct 15; 22(13):1936-42. PubMed ID: 17659636
    [Abstract] [Full Text] [Related]

  • 8. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.
    Cardiovasc Ther; 2011 Dec 15; 29(6):404-10. PubMed ID: 20553285
    [Abstract] [Full Text] [Related]

  • 9. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D.
    Lancet; 2004 Apr 10; 363(9416):1179-83. PubMed ID: 15081648
    [Abstract] [Full Text] [Related]

  • 10. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L.
    Arch Neurol; 2007 Dec 10; 64(12):1721-6. PubMed ID: 18071034
    [Abstract] [Full Text] [Related]

  • 11. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
    Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A.
    Mov Disord; 2007 Jan 15; 22(2):234-8. PubMed ID: 17094087
    [Abstract] [Full Text] [Related]

  • 12. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC, Bax JJ, van Hilten JJ, Jukema JW.
    Ned Tijdschr Geneeskd; 2005 Apr 16; 149(16):891-4. PubMed ID: 15868996
    [Abstract] [Full Text] [Related]

  • 13. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM.
    J Clin Endocrinol Metab; 2008 Sep 16; 93(9):3348-56. PubMed ID: 18559921
    [Abstract] [Full Text] [Related]

  • 14. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
    Nakaoka S, Ishizaki T, Urushihara H, Satoh T, Ikeda S, Morikawa K, Nakayama T.
    Intern Med; 2011 Sep 16; 50(7):687-94. PubMed ID: 21467699
    [Abstract] [Full Text] [Related]

  • 15. Bromocriptine use and the risk of valvular heart disease.
    Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC.
    Mov Disord; 2009 Feb 15; 24(3):344-9. PubMed ID: 18989898
    [Abstract] [Full Text] [Related]

  • 16. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
    Ooba N, Yamaguchi T, Kubota K.
    Drug Saf; 2011 Apr 01; 34(4):329-38. PubMed ID: 21417505
    [Abstract] [Full Text] [Related]

  • 17. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT.
    Intern Med J; 2009 Apr 01; 39(4):213-5. PubMed ID: 19402858
    [No Abstract] [Full Text] [Related]

  • 18. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Apr 01; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.